While our scientists, doctors and patients push the boundaries of medical science, it is crucial that we have evidence-based conversations about how to bring evidence-based medicines to those who need them.
A recent WHO technical report on the pricing of cancer medicines has sparked a lively debate on oncology spending and access to life-changing therapies. While we have fundamental concerns about the approach taken in the report, and the conclusions the authors reached, it offers opportunities for some fresh thinking on the future of cancer care.
For The Chance To...
Millions of people wouldn't be here today if it wasn't for life-changing science. And many more wouldn't be living the...
Read more
Data has the enormous potential to improve the health of patients around the world. Artificial intelligence (AI) systems...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.